Drug Search Results
More Filters [+]

Nintedanib

Alternative Names: nintedanib, vargatef, bibf 1120, bibf1120, Ofev
Latest Update: 2024-12-18
Latest Update Note: Clinical Trial Update

Product Description

Nintedanib is an approved treatment for IPF, which reduces the rate of decline in forced vital capacity (FVC).  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33902584/)

Mechanisms of Action: Apoptosis Inhibitor,VEGF Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis

Known Adverse Events: Hypertension | Abdominal Pain | Headache | Pain Unspecified | Diarrhea

Company: Boehringer Ingelheim
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Nintedanib

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czech Republic, Denmark, Finland, France, Germany, Greece, Hungary, India, Israel, Italy, Japan, Korea, Malaysia, Mexico, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, Thailand, Ukraine, United Kingdom, United States

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Bronchiolitis|COVID-19|Lung Diseases, Interstitial|Lymphangioleiomyomatosis|Pneumonia|Pulmonary Fibrosis|Scleroderma, General

Phase 2: Anthracosis|Asbestosis|Breast Cancer|Lung Cancer|Mesothelioma|Pneumoconiosis|Radiation Pneumonitis|Silicosis|Telangiectasia, Hereditary Hemorrhagic

Phase 1: Acute Myeloid Leukemia|Healthy Volunteers|Idiopathic Pulmonary Fibrosis|Progressive Pulmonary Fibrosis

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

InPedILD™-ON

P3

Active, not recruiting

Lung Diseases, Interstitial

2025-12-06

NU 17H04

P1

Active, not recruiting

Acute Myeloid Leukemia

2025-12-01

1199-0378

P3

Unknown Status

Lung Diseases, Interstitial

2025-08-11

InPedILD®-ON

P3

Active, not recruiting

Lung Diseases, Interstitial

2025-07-14

Recent News Events